SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs admitted affair with a business executive and the Nvidia boards independent investigation have drawn attention, with traders debating whether the unverified espionage allegations and potential leadership fallout pose a serious risk or are an overreaction unrelated to Nvidias AI business. Many are buying the selloff on confidence in the companys fundamentals, while others remain cautious about the investigation and possible CEO succession concerns.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is selling off after a weaker-than-expected Q3 report, with traders focused on the revenue decline, slowing commercial uptake and possible future dilution. The reaction is mixed: critics question execution and the cash outlook, while bullish traders argue the positive BCG-naive trial result and Israeli approval support the longer-term Anktiva story.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A sharp pre-earnings rally ahead of TTDs Q3 report has traders debating whether hopes for a turnaround and possible short covering are driving the move; others remain cautious given concerns about slowing growth and weak guidance.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clovers Q3 earnings beat and improved full-year outlook, alongside a profitable quarter and strong membership growth, are fueling renewed buying and a push to hold above $5. Traders are divided over whether the gains can stick, with some focused on the companys growth and others disappointed by the lack of concrete Counterpart Health software revenue updates.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims is in focus ahead of its quarterly results as traders weigh the Eli Lilly agreement to offer branded obesity drugs through its platform against concerns that the shift could pressure margins. The sharp decline has fueled speculation about disappointing results or an earnings leak, while others see the partnership and potential growth as reasons to stay bullish.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics BRIUMVI-driven quarterly beat and raised revenue outlook are drawing attention, but shares have fallen as traders debate a sell-the-news reaction versus a buying opportunity. The upcoming Phase 3 readout for subcutaneous BRIUMVI is widely viewed as the next major catalyst.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Jefferies Buy initiation and favorable Phase III prostate cancer data are drawing attention to Candels planned BLA filing for CAN-2409. Bulls see the results and recent immune-profile data as support for the regulatory case, while skeptics question filing execution, manufacturing readiness, financing needs and management transparency.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Debate over allegations of Webulls China ties and the fallout from a congressional report and securities lawsuits dominates discussion, with traders attributing the stocks weakness to a lingering China-related risk discount. Some see the upcoming earnings report and the companys growth as potential confidence builders, while skeptics say the overhang and poor performance versus peers remain unresolved.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Traders are linking ARWRs sharp decline to weak early sales for rival Ioniss Tryngolza, raising concerns about the commercial outlook for Arrowheads Redemplo despite some arguing its data and product profile are stronger. Others point to Arrowheads high cash burn and possible financing needs as added pressure.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs quarterly results and raised full-year revenue outlook are driving attention, with traders highlighting record growth, a larger backlog and strong demand for its quantum systems. While many view the report as a bullish signal, others question how much growth came from acquisitions and point to continued losses, cash burn and dilution risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IBRX Stock Crashes To Near 9-Month Lows On Q3 Earnings Miss – Retail Says No Way To Escape Further Dilution

The decline appears tied to ImmunityBios weaker-than-expected Q3 results: revenue was $48.8 million versus roughly $59.2 million expected, and the loss per share was wider than consensus. The positive QUILT-2.005 trial result and Israeli approval were outweighed by concerns about near-term sales growth and potential dilution.

Equity

ImmunityBio reported a first topline miss in six quarters after Q3 revenue came in at $48.8 million, sharply below Wall Street’s estimate of $59.2 million, according to Fiscal.ai.


ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of -25.00% and -19.60%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third quarter ended September 30, 2026. ImmunityBio continued to advance a broad clinical pipeline spanning bladder cancer...

ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ImmunityBio, Inc. (NASDAQ: IBRX) (ImmunityBio) and Rafa Laboratories Ltd. (TASE: RAFA) (Rafa) today announced that the Israeli Ministry of Health (MoH) has granted approval for ANKTIVA (nogapendekin alfa inbakicept), indicated in combination with Bacillus Calmette-Gurin (BCG) for the treatment of...

ImmunityBio Announces ANKTIVA Plus BCG Meets Primary Endpoint in BCG-Nave Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled, registrational trial evaluating intravesical ANKTIVA (nogapendekin alfa...

Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA — Geode Adds More 

Geode’s largest ownership stake was in Sellas at 3%, followed by Iovance at 2% and ImmunityBio at 1%.

Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down

AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.

SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline

Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.

ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up

Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.

Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y 

VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.

Bullish Sentiment

<ul class="summary-bullets"><li>The biotech firm posted a loss of $0.18 per share, wider than consensus estimates of about a $0.08 per-share loss.</li><li>Anktiva combined with BCG met the primary goal of a Phase 3 trial in BCG-Naïve NMIBC</li><li>Israel became the 35th country to approve Anktiva Plus BCG for BCG-Unresponsive NMIBC with Carcinoma in Situ with or without papillary tumors.</li></ul>ImmunityBio (IBRX) shares crashed nearly 19% on Monday as investors weighed the biotech firm’s weaker-than-expected third-quarter earnings, despite positive results from a late-stage bladder cancer trial and another international approval for its flagship treatment, Anktiva.<a class="mention" data-mention="$IBRX" data-symbol-id="IBRX" href="https://stocktwits.com/symbol/IBRX" target="_blank">IBRX shares</a> slumped to their lowest levels in nearly nine months. The stock is also on track to decisively break below the crucial 200-day moving average (200-DMA) for the first time since January.<img src="https://news.stocktwits-cdn.com/IBRX_2_7445052384.png" alt="IBRX (2).png"><h2 class="st-heading-2">Q3 Revenue And Earnings Miss Estimates</h2>ImmunityBio reported Q3 revenue of $48.8 million, sharply below Wall Street’s estimate of $59.2 million, according to Fiscal.ai. This was its first topline miss in six quarters. The company also posted a loss of $0.18 per share, wider than consensus estimates of about a $0.08 per-share loss.ImmunityBio said the net loss was mainly driven by changes in the fair value of a related-party convertible note, and warrant and derivative liabilities due to an increase in the stock price, higher R&amp;D and general and administrative expenses. It ended September with $334.3 million in cash, cash equivalents and marketable securities.<h2 class="st-heading-2">Anktiva + BCG Meets Phase 3 Trial Goal</h2>Separately, the retail-favorite biotech firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-anktivar-plus-bcg-meets-primary-endpoint">announced</a> that Anktiva combined with BCG met the primary goal of its Phase 3 Quilt-2.005 trial involving 370 patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC). The trial evaluated patients receiving BCG, a standard bladder cancer treatment, for the first time.The combination showed a statistically significant improvement in treatment response compared with BCG alone in patients with carcinoma in situ, a form of early-stage bladder cancer. ImmunityBio plans to seek FDA approval for the expanded indication by year-end.ImmunityBio also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-and-rafa-announce-israeli-ministry-health-approval">announced</a> approval of Anktiva plus BCG in Israel for patients with BCG-Unresponsive NMIBC with Carcinoma in Situ with or without papillary tumors. The approval expands Anktiva’s reach to 35 countries.<h2 class="st-heading-2">Retail Sees Downside Until Q2 2027</h2>While retail sentiment surrounding IBRX on Stocktwits improved to ‘neutral’ from ‘bearish’ over the past 24 hours, users highlighted the disappointing earnings.<img src="https://news.stocktwits-cdn.com/IBRX_S_b86e4e2e5f.png" alt="IBRX S.png">One user said it was a “Big miss on earnings,” adding that IBRX could see downside until the end of Q1 or Q2 next year.<stembedurl>https://stocktwits.com/The_Great_Gatsbear/message/668555521</stembedurl>Another user said, “There is no way we escape further dilution with that revenue miss.”<stembedurl>https://stocktwits.com/Rock801/message/668555769</stembedurl>ImmunityBio raised $28.5 million via an at-the-market (ATM) offering program in Q3.Despite Monday’s slump, IBRX has been among the top-performing biotech names this year, with shares surging more than 280%.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-ceo-sees-global-revenue-exceeding-1b-in-2026-briumvi-sales-q3/cNGrO9jR9eH">&nbsp;TG Therapeutics’ CEO Sees Global Revenue Exceeding $1B In 2026 – BRIUMVI Drives Q3 Topline Beat</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

ImmunityBio reported a first topline miss in six quarters after Q3 revenue came in at $48.8 million, sharply below Wall Street’s estimate of $59.2 million, according to Fiscal.ai.

SPDR S&P Biotech ETF

$SLS

$ONDS

$IBRX

$PYPL

Which of these trending stocks are you most bullish on right now - $SLS, $ONDS, $IBRX, or $PYPL?

Stocktwits

SELLAS Life Sciences Group Inc

Ondas Inc

PayPal Holdings Inc

Which of these trending stocks are you most bullish on right now - 

Stocktwits Polls

Investors are weighing the company's Q3 revenue decline and adjusted net loss against long-term growth prospects.

New data from the BCG-naïve trial meeting its primary endpoint is being highlighted as a major validator for the drug's efficacy.

Bullish traders view the double-digit price drop as a generational buying opportunity to accumulate shares at a discount.

The Ministry of Health's approval for ANKTIVA® has been added to the company's international commercialization momentum.

Retail investors are betting on institutional forced buying to trigger a potential reversal despite high levels of bearish sentiment.

Current Price	$6.82
Prev Close	$8.64
Open	$7.22
Dividend Yield	0.00%
50-Day Moving Average	$8.74
Beta	1.83
Avg. Volume	14.61M
PE Ratio	-8.91

52-Week High	$12.43
52-Week Low	$1.95
Market Capitalization	$9.15B
EPS (Annual)	-$0.382
Price to Book	-8.69
Revenue Per Employee	$163,947.90

Feed

News

Sentiment

Earnings

Fundamentals

Info

IBRX Fundamentals